Tibet Duo Rui Pharmaceutical Hits Day Low Amid Price Pressure at CNY 65.29

Tibet Duo Rui Pharmaceutical Co., Ltd. experienced significant volatility on March 27, 2026, with the stock declining by 12.64% and reaching an intraday low of CNY 65.29. This performance starkly contrasts with the China Shanghai Composite, which saw a modest gain of 0.63% on the same day. Over the past week, Tibet Duo Rui has faced a 15.61% drop, while its monthly performance reflects an 11.41% decline. Despite a remarkable annual return of 200%, the company has struggled with long-term growth, evidenced by a net sales decrease of 15.87% annually and a staggering operating profit decline of 376.81% over the last five years. The company's financial health raises concerns, highlighted by a debt-to-equity ratio of 0.05 and a return on equity of -28.67%. Additionally, Tibet Duo Rui has reported negative results for 13 consecutive quarters, indicating ongoing challenges in profitability. As a mid-cap player in the pharmaceuticals and biotechnology sector, the company continues to navigate a complex market landscape.